The procarcinogen hypothesis for bladder cancer: Activities of individual drug metabolizing enzymes as risk factors

Pharmacogenetics

Volumn 5, Issue , 1995, Pages S97-S102

  Branch, R A ^a   Chern, H D ^a   Adedoyin, A ^a   Sparks, M Romkes ^a   Lesnick, T G ^a   Persad, R ^b   Wilkinson, G R ^c   Fleming, C M ^c   Dickinson, A J ^d   Sibley, G ^d   Smith, P ^d  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c VANDERBILT UNIVERSITY   (United States)

^d UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOGEN; CYTOCHROME P450 ISOENZYME; DAPSONE; DEBRISOQUINE; DRUG METABOLIZING ENZYME; ENVIRONMENTAL CHEMICAL; MEPHENYTOIN; PROCARCINOGEN; UNCLASSIFIED DRUG;

ALCOHOL CONSUMPTION; BLADDER CANCER; CONFERENCE PAPER; DRUG METABOLISM; GENETIC POLYMORPHISM; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOTHESIS; METABOLIC ACTIVATION; OCCUPATIONAL EXPOSURE; PHENOTYPE; PRIORITY JOURNAL; RISK FACTOR;

BLADDER NEOPLASMS; CARCINOGENS; CASE-CONTROL STUDIES; COMPARATIVE STUDY; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; HUMAN; METABOLIC DETOXICATION, DRUG; MIXED FUNCTION OXYGENASES; PHENOTYPE; PRODRUGS; REFERENCE VALUES; RISK FACTORS; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0028998002     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199512001-00009     Document Type: Article

References (26)

1. Chern HD, Romkes-Sparks M, Persad R. Sibley GA, Smith PJB, Branch RA. Genotyping of CYP2D6 in a prospective cohort study of bladder cancer. Proceedings of the Fourth International Conference on Anticarcinogenesis of Radiation Protection. Mechanisms, Biomarkers, Molecular Diagnostics and Prevention Strategies. 1993: 94.
2. Chern HD, Romkes-Sparks M, Hu JJ, Persad R, Sibley GA. Smith PJB, Branch RA. Homozygous deleted genotype of glutathione S-transferase Ml increases susceptibility to aggressive bladder cancer. Proceedings of the 85th Annual Meeting of the American Association for Cancer Research. 1994: 35, 285.
3. Eichelbaum M, Gross AS. The genetic polymorphism of debriso-quine/sparteine metabolism - clinical aspects. Pharmacol Ther 1990: 46, 377-394.
4. Fleming CM, Branch RA, Wilkinson GR. Guengerich FP. Human liver microsomal N-hydroxylation of dapsone by cytochrome P4503A4. Mol Pharmacol 1992a: 41, 975-980.
5. Fleming CM, Kaisary A, Wilkinson GR, Smith P, Branch RA. Recurrence of bladder cancer is associated with cytochrome P450IID6 (debrisoquine hydroxylase) activity. Pharmacogenetics 1992b: 2, 128-134.
6. Fleming CM, Persad R, Kaisary A, Smith P, Adedoyin A, Porter J, Wilkinson GR, Branch RA. Low activity of dapsone N-hydroxylation as a susceptibility risk factor in aggressive bladder cancer. Pharmacogenetics (in press).
7. Frye RF, Matzke GR, Stiff DD, Adedoyin A, Porter J, Kubisty C, Branch RA. Validation of a five drug cocktail for use in population phenotyping. Pharm. Res 1993: 10(10). S-388.
8. Gaedigk A, Blum M, Gaedigk R, Eichelbaum M, Meyer UA. Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism. Am J Hum Genet 1991: 48, 943-950.
9. Goldstein JA, Faletto MB, Romkes-Sparks M, Sullivant T, Kitaree-wan S, Raucy JL, Lasker JM, Ghanayem BJ. Evidence that CYP2C19 is the major S-mephenytoin 4'-hydroxylase in humans. Biochemistry 1994: 33, 1743-1752.
10. Gough AC, Miles JS, Spurr NK, Moss JE, Gaedigk A, Eichelbaum M, Wolf CR. Identification of the primary gene defect at the cytochrome P450 CYP2D locus. Nature 1990: 347, 773-776.
11. Hanioka N, Kimura S, Meyer UA, Gonzalez FJ. The human CYP2D locus associated with a common genetic defect in drug oxidation: A G1934-> A base change in intron 3 of a mutant CYP2D6 allele results in aberrant 3 prime splice recognition site. Am J Hum Genet 1990: 47, 994-1001.
12. Harris CC. Chemical and physical carcinogenesis: advance and perspectives for the 1990s. Cancer Res 1991: 51, 5023s-5044s.
13. Heim M, Meyer U. Genotyping poor metabolizers of debrisoquine by allele-specific PCR amplification. Lancet 1990: 336, 529-532.
14. International Agency for Research on Cancer (IARC): Monographs on the evaluation of the carcinogenic risk of chemicals in humans. International Agency for Research on Cancer 1986 Lyon, France, Vol. 38.
15. Jacqz E, Hall S, Branch RA. Genetically determined polymorphisms in oxidative drug metabolism. Hepatology 1986: 6, 1020-1032.
16. Kaisary A, Smith P, Jacqz E, McAllister CB, Wilkinson GR, Ray WA, Branch RA. Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and mephenytoin as risk factors. Cancer Res 1987: 47, 5488-5493.
17. Lower GM. Concepts in causality: chemically induced human bladder cancer. Cancer 1982: 49, 1056-1066.
18. May G, Porter JA, Uetrecht JP, Wilkinson GP, Branch RA. The contribution of N-hydroxylation and acetylation to dapsone pharmacokinetics in normal subjects. Clin Pharmacol Ther 1990: 48, 619-627.
19. May DG, Arns PA, Richards WO, Porter JA, Ryder D, Fleming CM, Wilkinson GR, Branch RA. Influence of cirrhosis on the disposition of dapsone. Clin Pharmacol Ther 1992: 51, 689-700.
20. May DG, Porter J, Wilkinson GR, Branch RA. Frequency distribution of dapsone N-hydroxylase - A putative probe for P4503A4 activity in a Caucasian population. Clin Pharmacol Ther 1994: 55, 492-500.
21. Miller JA, Miller EC. Some historical aspects of N-aryl carcinogens and their metabolic activation. Environ Health Perspect 1983: 49, 3-12.
22. de Morais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994: 269, 15419-15422.
23. Nebert DW, Nelson DR, Coon MJ, Estabrook RW, Feyereisen R, Fujii-Kuriyama Y, Gonzalez FJ, Guengerich FP, Gunsalus IC, Johnson EF, Loper JC, Sato R, Waterman MR, Waxman DJ. The P450 superfamily: update on new sequence, gene mapping and recommended nomenclature. DNA and Cell Biol 1991: 10, 1-14.
24. Shimada T, Iwasaki M, Martin M, Guengerich FP. Human liver microcomal cytochrome P-450 enzymes involved in the bioactivation of procarcinogens detected by the umu gene response in Salmonella typhimurium TA 1535/pSK1002. Cancer Res 1989: 49, 3218-3228.
25. Silverberg E, Boring C, Squire T. Cancer statistics 1990. Cancer J Clin 1990: 40, 9-26.
26. Wilkinson GR, Guengerich FP, Branch RA. Genetic polymorphism of S-mephenytoin hydroxylation. Pharmacol Ther 1989: 43, 53-76.